AstraZeneca_NNP Annual_JJ Report_NNP and_CC 90_CD Form_NN 20-F_JJ Information_NN 2005_CD NOTES_NNS TO_TO THE_DT FINANCIAL_NNP STATEMENTS_NNS 1_CD OPERATING_NNP PROFIT_NNP 2005 2004 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD Group_NNP operating_NN profit_NN 6,502_CD 4,547_CD 4,007_CD Charges_NNS included_VBD above_IN for_IN depreciation_NN 965 921 990_CD for_IN amortisation_NN 272 306 296_CD for_IN impairment_NN 90_CD 41_CD 7_CD Gross_NNP profit_NN 18,594_CD 16,233_CD 14,386_CD Impairment_NN charges_NNS in_IN 2005_CD relate_VBP to_TO the_DT write-down_NN of_IN assets_NNS associated_VBN with_IN capacity_NN reviews_NNS at_IN manufacturing_VBG sites_NNS ,_, primarily_RB in_IN the_DT UK_NNP and_CC France_NNP ._.
Cost_NN of_IN sales_NNS in_IN 2004_CD includes_VBZ charges_NNS against_IN inventories_NNS and_CC prepayments_NNS in_IN respect_NN of_IN Exanta_NNP and_CC Iressa_NNP totalling_VBG $_$ 195m_CD ._.
In_IN addition_NN ,_, the_DT charge_NN for_IN impairment_NN in_IN 2004_CD arose_VBD from_IN writing_VBG off_RP property_NN ,_, plant_NN and_CC equipment_NN and_CC goodwill_NN associated_VBN with_IN Exanta_NNP and_CC Iressa_NNP ._.
2005 2004 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD Other_JJ operating_NN income_NN Royalties_NNS 165_CD 95_CD 90_CD Other_JJ income_NN 28_CD 131 98 193 226_CD 188_CD Other_JJ income_NN includes_VBZ minor_JJ gains_NNS and_CC losses_NNS arising_VBG from_IN disposals_NNS under_IN ongoing_JJ product_NN and_CC investment_NN rationalisation_NN programs_NNS ._.
2_CD PROFIT_NNP ON_NNP SALE_NNP OF_IN INTEREST_NN IN_IN JOINT_NNP VENTURE_NNP 2005 2004 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD Profit_NN on_IN sale_NN of_IN interest_NN in_IN joint_JJ venture_NN 219_CD Net_JJ taxation_NN credit_NN 9_CD Total_JJ profit_NN on_IN sale_NN of_IN interest_NN in_IN joint_JJ venture_NN after_IN taxation_NN 228_CD The_DT profit_NN on_IN sale_NN of_IN interest_NN in_IN joint_JJ venture_NN relates_VBZ to_TO the_DT disposal_NN of_IN the_DT Groups_NNS interest_NN in_IN the_DT Ordinary_NNP Share_NN capital_NN of_IN Advanta_NNP BV_NNP ._.
There_EX is_VBZ a_DT tax_NN credit_NN of_IN $_$ 9m_CD arising_VBG on_IN costs_NNS associated_VBN with_IN the_DT disposal_NN ._.
3_CD FINANCE_NN INCOME_NN AND_CC EXPENSE_NN 2005 2004 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD Finance_NNP income_NN Securities_NNP 15_CD 10_CD 21_CD Short_JJ term_NN deposits_NNS 197_CD 81_CD 62_CD Expected_VBN return_NN on_IN post-employment_NN defined_VBN benefit_NN plan_NN assets_NNS 448 390 277_CD Gain_NN on_IN disposal_NN of_IN interest_NN rate_NN swap_NN 30_CD Dividend_NN income_NN 62_CD Net_JJ exchange_NN gains_NNS 5_CD 15 19 665 532_CD 381_CD Finance_NNP expense_NN Loan_NN interest_NN 42_CD 29_CD 6_CD Interest_NN on_IN short_JJ term_NN borrowings_NNS and_CC other_JJ financing_NN costs_NNS 19_CD 17_CD 6_CD Discount_NNP on_IN liability_NN 3_CD Interest_NN on_IN post-employment_NN defined_VBN benefit_NN plan_NN liabilities_NNS 433 398 284_CD Fair_NNP value_NN losses_NNS on_IN interest_NN rate_NN swaps_NNS 6_CD 10 12 500 454_CD 311_CD Net_NN finance_NN income_NN 165_CD 78_CD 70_CD The_DT amount_NN of_IN exchange_NN gains_NNS recognized_VBN in_IN profit_NN or_CC loss_NN ,_, other_JJ than_IN those_DT arising_VBG on_IN financial_JJ instruments_NNS measured_VBN at_IN fair_JJ value_NN through_IN profit_NN or_CC loss_NN in_IN accordance_NN with_IN IAS_NNP 39_CD see_VBP Note_VB 15_CD ,_, is_VBZ $_$ 5m_CD 2004_CD $_$ 15m_CD ,_, 2003_CD $_$ 19m_CD ._.
